Hims & Hers health executive sells $63,402 in stock

Irene Becklund, an officer at Hims & Hers Health, Inc. (NYSE:HIMS), recently sold shares of the company’s stock, according to a filing with the Securities and Exchange Commission. On April 3, Becklund sold 2,203 shares of Class A Common Stock at a price of $28.78 per share, resulting in a total transaction value of $63,402. Following this sale, Becklund holds 8,007 shares directly. The transaction was carried out under a Rule 10b5-1 trading plan adopted on August 7, 2024. The stock, which has shown significant volatility, has delivered an impressive 90.67% return over the past year. Want deeper insights into insider trading patterns and comprehensive analysis? Access the full HIMS Pro Research Report, along with 1,400+ other detailed company analyses, on InvestingPro.

In other recent news, Hims & Hers Health, Inc. has announced the expansion of its product lineup to include Eli Lilly (NYSE:LLY)’s diabetes and weight-loss drug Zepbound, along with generic versions of liraglutide. This move has positioned the company alongside competitors like Teladoc (NYSE:TDOC) and LifeMD in offering these medications through their telehealth platform. The expansion comes as the industry anticipates upcoming restrictions on compounded drugs, making this a strategic decision for Hims & Hers. Analysts have weighed in on this development, with Truist Securities maintaining a Hold rating and a $39 price target, noting the potential marketing benefits of the new offerings. Leerink Partners also maintained a Market Perform rating with a $40 target, emphasizing the need to observe the market’s reception to these products. Meanwhile, BofA Securities has maintained an Underperform rating with a $22 target, indicating skepticism about the financial impact of these new offerings. Despite varying analyst opinions, the company’s shares saw a positive response, reflecting investor optimism about the expanded product range. As Hims & Hers continues to diversify its offerings, the impact on its financial performance and market position will be closely monitored by investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.